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Objective: The present cohort study was performed to investigate the impact of the factor 5 rs6025 [F5] and
the factor 2 rs1799963 [F2] mutations on high-titer inhibitor development [HRI] in patients with severe/
moderate-severe hemophilia A [HA].
Patients and Methods: 216 patients with F8 b 2% born between 1980 and 2011 were followed after initial HA
diagnosis over the ﬁrst 200 exposure days. The ﬁrst HA patient per family who presented for diagnosis was
included in the present study.
Results: 32 of 216 children [14.8%] tested for F5/F2 carried either the F5 or the F2 variant. HRI occurred in 14 out of
32 F5/F2-carriers compared with 40 of 184 without F5/F2. Multivariate analysis adjusted for F8 genotype,
treatment intensity, ﬁrst-line use of plasma derived FVIII versus recombinant FVIII concentrates revealed that
the presence of F5/F2 independently increases the risk of HRI development to odds [OR] of 3.4. Large deletions
in the F8 gene [OR: 5.10], patients from Israel [OR: 4.0], the increase of FVIII per one IU/kgbw [OR: 1.05] and
birth year [OR: 1.12] were signiﬁcantly associated with the risk to develop HRI.
Conclusion: Data presented here suggest that HRI development is of multifactorial origin and that F5 and F2
mutations may contribute to this risk.© 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.ys; F2, Factor 2 rs1799963; F5,
; HA, hemophilia A; HRI, high-
H, intracranial hemorrhage; IFS,
ombophilic risk factor; OR/CI,
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.Open access under CC BY-NC-ND licIntroduction
The development of inhibitor antibodies against factor VIII [FVIII] is
one of the most important clinical challenges for patients with hemo-
philia A and their treating physicians, with important implications
with respect to patient’s health and socio-economic burden [1]. Apart
from non-modiﬁable risk factors for inhibitor development, such as
underlying severity [FVIII level at baseline], the genetic background
[type of F8 gene mutation], and a positive family history of inhibitor
development [in part related to inherited mutation type], research has
emphasized the role of modiﬁable risk factors, with treatment-related
risks as the most important candidates [2–5]. Among treatment-
related risk factors, the use of recombinant FVIII [rFVIII] concentrates
or high dose FVIII administration have been controversially debated as
risk factors for inhibitor development [2,4,5]. In a recent systematicense.
Fig. 1. Flow chart: study population break-down by inclusion and exclusion criteria.
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has been shown that possible confounders such as Factor VIII products
must be carefully considered when drawing conclusions from the anal-
ysis of observational data, while awaiting results of prospective ran-
domized and adequately powered multicenter studies [6].
The clinical phenotype of hemophilia A is not always explained by its
underlying F8 genotype, and it has been controversially discussed if the
phenotype of severe hemophilia A [HA] is inﬂuenced by co-inheritance
of the factor 5 rs6025 [F5] mutation [7–15]. In a German cohort study
we demonstrated that the ﬁrst symptomatic bleeding onset in children
with severe HA carrying the F5 or the factor 2 rs1799963 [F2] variant
was signiﬁcantly later in life than in non-carriers [10] In the latter cohort
a protective effect of thrombophilic risk factors [IT] was shown for the
annual bleeding frequency and the severity of the hemophilic arthropa-
thy] [12]. In contrast, however, in a further adequately powered adult
HA cohort this association could not be completely conﬁrmed: [15] in
100 adolescent and adult patients with hemophilia A or B from
Sweden Shulman and colleagues found that the clinical severity of he-
mophilia measured by a hemophilia risk score appeared to be modiﬁed
by the F2 mutation but not by coinheritance of the F5 variant. Further-
more, in an animal model the effect of the F5 polymorphism to improve
the hemophilic phenotype was restricted at the microcirculation level
followed by vascular injury [14].
The present cohort studywas performed to investigate the impact of
the F5 and F2 mutations on clinical meaningful high responding inhibi-
tor development [outcome variable] in white children with severe/
moderate-severe HA.
Methods
Ethics
The present multicenter database study in consecutively recruited
pediatric patients with HA which were prospectively followed for the
development of HR inhibitor development by the participating centers
was performed in accordance with the ethical standards laid down in
a relevant version of the 1964 Declaration of Helsinki andwas approved
by the Medical Ethics Committee of the University of Münster,
Germany. The present cohort study was reported in accordance to
STROBE guidelines for observational studies [16].
Inclusion/Exclusion Criteria
Inclusion and exclusion criteria are shown in Fig. 1. Previously
untreated patients [PUPs] with severe/moderate-severe HA aged
neonate to ≤18 years, who had been admitted to the University
Children's Hospitals of Frankfurt, Halle, the MVZ Duisburg, Kiel-
Lubbock, Munich, Münster, Germany and the Hemophilia Treatment
Center Tel-Hashomer, Israel, at ﬁrst symptomatic onset of the disease
were enrolled [5,10,12,17]. Patients born before 1980, pediatric patients
with HA additionally carrying vonWillebrand disease, childrenwith HA
≥ 2%, and HA patients not tested for the factor 5 and F2 mutation [no
parental/patient consent] were not included in this cohort study. In
addition, children pretreated with transfusion of red blood cell concen-
trate or fresh frozen plasma before the ﬁrst administration of FVIII con-
centrate, were not enrolled. To avoid family cluster effects in both
countries only the ﬁrst HA patient within a given family who presented
for diagnosis at the treatment center was included in the present study.
Outcome Measures
Inhibitor-free survival time [IFS: ﬁrst 200 exposure days (ED)]
related to presence or absence to F5 or F2 mutations: HA patients
carrying the F5 or 2 mutation were compared with subjects not
carrying the above mentioned F5 or F2 variants. Further debated vari-
ables were F8 gene mutations, ﬁrst-line use of plasma-derived [pd]versus rFVIII concentrates [2–5] and individual median single FVIII dos-
age [per IU/kg bodyweight] administered over the ﬁrst three months of
treatment as a proxy for treatment intensity. In addition adjustment
was performed for treatment periods [year of birth] and country of pa-
tient origin, i.e. Israel or Germany. From 1980 to 2011, 281 consecutive
pediatric PUPs of Caucasian origin with a ﬁrst symptomatic onset of HA
b 2% residual FVIII activity were ascertained: From these patients 65 in-
dividuals were excluded because of i) non-testing for thrombophilia, ii)
pretreatment with blood products, iii) co-expression of vonWillebrand
syndrome or iv) non-consent. Off note: 54 of 281 children which were
not tested for thrombophilia were equally distributed within the
study centers and did not differ with respect to inhibitor development
[n= 13]. The ﬁnal study cohort included 216 unrelated children [Fig. 1].
Treatment
At the discretion of the participating centers and according to stan-
dard of care in the years of patient enrollment children were either
treated with primary prophylaxis or with secondary prophylaxis. The
opportunity of primary prophylaxis was offered to all newly diagnosed
patients independent from age at presentation. The treatment regimens
were maintained as standard over time and the treatment regimens
were administered without knowledge of the individual thrombophilia
status, with no difference between carriers and non-carriers of F5/F2
[18–20]. For patients presenting with severe soft tissue bleeding at HA
onset an intensiﬁed treatment protocol was introduced in the mid-
1990s. These children received a primary prophylactic treatment regi-
men following the ﬁrst symptomatic hemorrhage [three times per
week]. In cases of trauma-associated or large spontaneous hemorrhage
two to three daily FVIII infusions were administered for a minimum of
ﬁve to seven days. The latter treatment episodes were classiﬁed as “in-
tensiﬁed treatment moments”.
Data Collection
baseline FVIII, F8 genotype, age at ﬁrst FVIII infusion, FVIII brand,
median single dosage administered over the ﬁrst three months of
546 G. Kenet et al. / Thrombosis Research 133 (2014) 544–549treatment, frequency of weekly factor administration, clinical bleeding
situations requiring intensive FVIII administration, such as intracerebral
hemorrhage [ICH], liver rupture or surgery, ethnicity, family history of
inhibitor development, country of patient origin, results of inhibitor
measurements, and FVIII ED and carrier status of thrombophilia, i.e. fac-
tor 5 and factor 2 variants and antithrombin, protein C and protein S de-
ﬁciency were collected.
Laboratory Analysis
Plasma levels of FVIII were determined by one-stage clotting assays
using standard laboratory methods. Inhibitor testing was performed at
least monthly when on therapy using the Bethesda method or its mod-
iﬁcation [Nijmegen]: The lower detection limit was set according to the
inhibitor assay used in each study center, and a peak inhibitor titer of N5
BU was deﬁned as high-titer antibody. Inhibitor positivity was stated
when an inhibitor was measured at least in two independent follow-
up visits.
Statistics
Statistical analyseswere performedwith theMedCalc software [ver-
sion 12.3.0] and the StatView 5 software package [SAS Institute Inc.].
Continuous data were presented as median/interquartile range [IQR]
orminimum-maximumvalues, and evaluated bynon-parametric statis-
tics using theWilcoxon-Mann–Whitney U test. Frequency distributions
of adverse outcome and possible interactions within independent vari-
ableswere comparedwith chi-square test or, if necessary, Fisher’s exact
test. IFS, deﬁned as the number of cumulative ED until inhibitor devel-
opment, was calculated by Kaplan-Meier method, and compared be-
tween groups by Cox proportional hazard modeling with calculation
of hazard ratios [HRs]/95% conﬁdence intervals [CIs]. The effect of vari-
ables possibly associated with HRI development and variables of inter-
est in bivariate analysis [ﬁrst-line use of pd- versus rFVIII concentrates,
F8 genotypes [one categorical variablewithﬁve options] [21], individual
median single FVIII dose administered over the ﬁrst three months, year
of birth [continuous variable; proxy for different treatment periods],Table 1a
Patient characteristics and rates of HR inhibitor development by country is shown.
Years of birth
Ethnicity
Caucasian (%)
Factor concentrates used [n]
- pdFVIII
- rFVIII
Median [IQR] single dose FVIII [IU/kg/bw]
Thrombophilia status: number [%]
- F 5
- F 2
Persistent high responding inhibitor [N5 BU]
Indications for intensiﬁed treatment prior to HR inhibitor development:
Total: number
- neonatal ICH
- cephalohematoma
- liver rupture
- head/spinal trauma
- knee or ankle bleed
- tongue bleed
- appendectomy
- meatotomy
- nephroblastoma
Abbreviations: BU: Bethesda Units; F2: Factor 2 rs1799963; F5: Factor 5 rs6025; ICH: intrac
thrombophilia; pd: plasma derived; r: recombinant.country of patient origin] within the observation period of 200 ED was
assessed by multivariate analyses [logistic regression]: Odds ratio
[ORs] and 95% CIs were calculated. P-values b 0.05 were considered sig-
niﬁcant. The quality of the logistic regressionmodel was testedwith the
Hosmer-Lemeshow goodness-of-ﬁt test. Off note: As HRI generally de-
velops in a short time period after FVIII substitution time to inhibitor de-
velopment is negligible: therefore logistic regression rather than Cox
proportional-hazards regressionwas chosen in this study design [medi-
an of 22 EDs]. In addition, since we have recently shown that Israeli and
German HA patients with FVIII activity b1% did not differ from HA chil-
dren with FVIII activities between 1% to b2%with respect to underlying
HA genotypes and clinical phenotypes patients with a remaining FVIII
activity b2% were analyzed together [17].
Results
Study Population
The characteristics of the ﬁnal study population are shown in
Tables 1a and 1b. According to inclusion and exclusion criteria the
ﬁnal study cohort ascertained from 1980 to 2011 included 216 PUPs
with HA b 2%. In the HA patients investigated, the overall heterozygous
F5 [n = 22] or F2 [n = 10] carrier frequency was 14.8%: 19.6% in the
Israeli cohort and 12.9% in Germany [p = 0.3]. In the present cohort
no patient was a homozygous or double heterozygous F5/F2 carrier.
None of the children with HA b2% carried antithrombin-, protein C–
or protein S-deﬁciency. The median [IQR] single FVIII administered
over the ﬁrst three months of treatment and themedian weekly substi-
tution intervals on prophylaxis prior to inhibitor development are
shown in Table 1a. For trauma-associated hemorrhage an intensiﬁed
FVIII administration was documented.
HR Inhibitor Development - Descriptive & Bivariate Analysis
Within a median [minimum-maximum] time period of 22 [8–172]
EDs 54 of 216 children [25%] developed HRI. The distribution of under-
lying F8 genemutations is shown in the suppl. material [Fig. 1]. Four outIsrael
N = 61
Germany
N = 155
Total
N = 216
1980 – 2011 1980 – 2011 1980 – 2011
100 100 100
34 100 134
27 55 82
30 [17] 38 [30] 35 [25]
9 [14.7] 13 [8.4] 22 [10.2]
4 [6.6] 6 [3.9] 10 [4.6]
23 [37%] 31 [20%] 54 [25%]
12 16 28
2 4 6
1 5 6
- 1 1
4 - 4
1 3 4
1 3 4
1 - 1
1 - 1
1 - 1
ranial hemorrhage; IQR: interquartile range kgbw: kilogram bodyweight; IT: inherited
Table 1b
Patient characteristics by inhibitor development is shown.
No
inhibitor
N = 162
High-titre
inhibitor
N = 54
Total
N = 216
Years of birth:
Median [IQR] 1990
[10]
1994 [17] 1991 [11]
Factor concentrates used: number
- pdFVIII 106 28 134
- rFVIII 56 26 82
Median [IQR] single dose FVIII [IU/kg/bw] 32 [20] 50 [36] 35 [25]
Median [minimum-maximum] weekly
substitution interval
3 [1–3] 3 [1–4] 3 [1–4]
Thrombophilia status: number 18 14 32
- F5 11 11 22
- F2 7 3 10
High risk gene mutations: number 49 30 79
Exposure days to HRI development:
median [IQR]
- 22 [30] -
Abbreviations: F2: Factor 2 rs1799963; F5: Factor 5 rs6025; HRI: high-titre inhibitor; IQR:
interquartile range; kgbw: kilogram bodyweight; pd: plasma derived; r: recombinant.
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apy [EDs: 12, 18, 22 & 23], 50 patients developed HRI while on primary
or secondary prophylaxis. In 10 of 28 children [35.7%] with intensiﬁed
FVIII administration due to trauma-associated or spontaneous hemor-
rhage HRI were detected. In this subgroup one neonate with ICH out
of 10 children with HRI receiving intensiﬁed FVIII substitution carried
additionally the F5 mutation. Higher factor VIII doses administered in
the latter 10 children contributed to the higher factor VIII doses admin-
istered in children with HRI (Table 1b). HRI occurred in 14 [F5: n = 11;
F2: n = 3] out of 32 carriers of IT [44%] compared with 40 of 184 [22%]
without IT [P = 0.009]. The IFS in patients carrying F5 or F2 mutations
was decreased as compared to patients without IT [Fig. 2]. The differ-
ence in cumulative IFS was statistically signiﬁcant [HR/95%CIs: 3.07/
1.4-6.9].
No statistically signiﬁcant interactions were found between F5/F2
carriers and i) the presence of F8 genotypes [p = 0.93; data are
shown in suppl. Fig. 2] or ii) children treated with intensiﬁed FVIII
administrations [p = 0.73].Fig. 2. Cumulative inhibitor-free survival of patients with HA b 2% in children with and
without F5 or F2 variant.Inhibitor Development - Multivariate Analysis
Multivariate analysis [logistic regression] adjusted for F8 genotype,
ﬁrst-line use of pdFVIII [n = 134] versus rFVIII concentrates [n = 82],
patient’s individualmedian single FVIII dose, the year of birth and coun-
try of origin revealed that the presence of F5/F2 independently in-
creased the risk of inhibitor development, with an odds ratio of 3.4
[CI: 1.33-8.7]. In addition, patients carrying the F8 genotype “large dele-
tion” [OR/95%CI: 5.10/1.12-23.17], children enrolled from Israel [OR/
95%CI: 4.0 [1.45-11.0], the increase of FVIII per one IU/kgbw [OR/
95%CI: 1.05/1.02-1.08] and the year of birth [OR/95%CI: 1.12/1.05-
1.20] were signiﬁcantly associated with the risk to develop a HRI. Chil-
dren born in the nineties towards 2011 [latest year of birth] showed a
higher rate of inhibitor development compared to children treated in
the eighties. There was a weak but statistically signiﬁcant correlation
between each increasing year of birth [1980 – 2011] and occurrence of
HRI [rho = 0.297; 95% CIs: 0.17-0.41]. Findings of bi- and multivariate
analyses are summarized in Table 2 [the variables are adjusted for
each other]. The Hosmer-Lemeshow goodness-of-ﬁt P-value was 0.88.
Results of Cox proportional-hazards-regression analysis are shown in
suppl. Table 1. Results calculated for the subgroup of 192 children
with HA b 1%were comparable to the entire study group [Data- logistic
regression & Coxproportional hazards regression analysis- are shown in
suppl. Table 2].Discussion
The data reported in the present cohort study demonstrate that the
development of a HRI in childrenwithHA b 2% is ofmultifactorial origin.
In addition to the known risk factors associated with inhibitor develop-
ment, we have shown that the presence of F5 or F2mutations in the het-
erozygous state did not only modify the clinical phenotype of HA [7,8]
but have been shown to be independent risk factors for inhibitor devel-
opment. Of note, the prevalence of both mutations was within preva-
lence rates reported in the general Israeli and German population
[22–24]. Here we speculate, that the carrier status of the F5 or F2muta-
tion contributes to HRI development in the cohorts investigated.
The mechanism by which patients with HA b 2% additionally carry-
ing the F5 or F2mutation are prone to a higher risk to develop inhibitorsTable 2
Unadjusted [univariate] and adjusted [multivariate] odds ratios [OR] and 95% conﬁdence
intervals [CIs] are shown. Variables in multivariate analysis are adjusted for each other.
Parameter investigated Unadjusted OR/CIs Adjusted OR/CIs
Comparator: no F5/F2
F5 or F2 carrier status 2.9 [1.32-6.3] 3.4 [1.33-8.7]
Comparator: intron 22 inversion
Large deletions 3.61 [1.01-12.86] 5.10 [1.12-23.17]
Nonsense mutations 0.9 [0.24-3.42] 1.47 [0.30-7.19]
Missense mutations 0.33 [0.13-0.77] 0.27 [0.09-0.85]
Small deletions/insertions/splice-site
mutations
0.08 [0.02-0.30] 0.06 [0.01-0.30]
Increase per one IU/kgbw
Median single FVIII dose 1.05 [1.03-1.07] 1.05 [1.02-1.08]
Comparator: pdFVIII
rFVIII 1.75 [0.97-3.3] 1.92 [0.73-4.99]
Per year of birth [1980 towards 2011]
Year of birth 1.09 [1.05-1.14] 1.12 [1.05-1.20]
Comparator Germany
Country of origin 2.5 [1.3-4.8] 4.0 [1.45-11.01]
Abbreviations: F2: Factor 2 rs1799963; F5: Factor 5 rs6025; kgbw: kilogram bodyweight.
* inversions, large or small deletions, nonsense, missense, splice and frameshiftmutations.
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children with the F5 or F2 mutation had a later bleeding onset [10]
and that both thrombophilic mutations may protect from blood
loss in adults [11] and reduce joint damage in children [11], we hy-
pothesize that in patients with the aforementioned thrombophilic
changes in case of a clinically relevant bleeding i) a more severe ex-
ogenous trigger is needed to let the patient bleed, with ii) a higher
peak dose of factor FVIII to be used to stop the hemorrhage [25]. In
addition, children who bleed less severely do frequently show up
later in the hemophilia treatment centre with a larger untreated
hemorrhage. Thus, a more severe trigger along with a larger amount
of blood, possibly leading to a higher degree of cell and tissue dam-
age, consequently may lead to a more intensive activation of the so
called “danger signals” [26–29]. It has been reported that in individ-
uals with thrombophilia increased thrombin generation is observed
[30–32]. In addition, Skupsky and colleagues demonstrated in an an-
imal model that thrombin formation through the procoagulant activ-
ity of FVIII is necessary to induce co-stimulation for the immune
response to FVII treatment [33]. As thrombin is a potential “danger
signal”, the children who are treated with higher FVIII doses due to
occurrence of larger bleeds as previously explained, are more sus-
ceptible to inhibitor formation. Danger signals, ﬁrst discussed in
1994 [26], can be induced by bleeding associated tissue or cell-
damage and stimulate inﬂammatory responses of the immune sys-
tem, thereby up-regulating antibody responses, with the here spec-
ulated consequence of HR development against FVIII.
In our multivariate analyses we also showed that the individual
FVIII dose administered over the ﬁrst three months of treatment
and the year of birth did play a role in the HR inhibitor development.
In contrast, the controversially discussed risk of rFVIII over the use of
pdFVIII concentrate did not reach signiﬁcance in the present analy-
ses. This ﬁnding is in line with data of the CANAL and RODIN cohort
studies [3,21,34] and a recently published meta-analysis on observa-
tional trials [4]. Notably, inclusion of “year of birth” in the analytic
model was responsible for the decrease of the odds of type of FVIII
concentrate, underlining the importance of concurrent comparison
between product types.
Limitations of this multicenter study include the long ascertain-
ment period from 1980 to 2011. This latter characteristic increases
the potential for time-period effects linked to changes in clinical
practice that may in turn impact risk for HRI development. However,
similar to the reported Canadian hemophilic cohorts [20], our pa-
tients have been on treatment protocols that remained unchanged
with respect to treatment indications. In the Canadian cohort and
our cohort, a similar increasing preference of prophylactic treatment
regimens was observed since the late eighties/mid-nineties. Since
the treatment regimens were administered without knowledge of
the individual F5/F2 status [5,10,12], with no difference between car-
riers and non-carriers of thrombophilia, our observation gives evi-
dence that the thrombophilic gene mutations truly contribute to
the higher inhibitor frequency in the children reported. An addition-
al potential limitation is the restriction of the cohort data to a bi-
national sample. In particular, to the extent that the prevalence
rates of the F5 and F2 variants in Israel and Germany differ from
those in other countries, caution should be exercised in generalizing
the ﬁndings to other nationalities. Finally we are aware that although
the study cohort is small, it is one of the largest continuously recruit-
ed pediatric HA patient cohort. Thus, based on the small sample size
as further study limitation we have to discuss the lack of power to
detect signiﬁcant study results. This mainly affects a type II error,
i.e. the mistake not to see an association between F5/F2 status and
inhibitor development which, however, is not the case in the present
study because we could show a statistically signiﬁcant association
also in multivariate analysis.
In conclusion, data presented here suggest that development of HR
inhibitors is of multifactorial origin in which, apart from a positivefamily history of inhibitors, presence of F5 and F2 mutations should be
investigated.
Contribution of the present study to the understanding of inhibitor development in
children with hemophilia A.
What is known about the topic
• Genetic and treatment related variables play a role in high
titer inhibitor development in patients with hemophilia A
What does the paper add
• Multivariate analysis adjusted for F8 genotype, treatment
intensity, ﬁrst-line use of plasma derived FVIII versus
recombinant FVIII concentrates revealed that the presence
of F5 rs6025 or F2 rs1799963 independently increases the
risk of HRI development to odds of 3.4.
• Data presented here suggest that high titer inhibitor
development is of multifactorial origin and that F5
rs6025 or F2 rs1799963 may contribute to this risk.
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